Loading clinical trials...

Protective Effect of N-acetylcysteine Against From Ototoxicity | Clinical Trials | Clareo Health

COMPLETEDPHASE2/PHASE3

Protective Effect of N-acetylcysteine Against From Ototoxicity

Phase 3 Study of Protective Effect of N-acetylcysteine Against From Ototoxicity

NCT01271088•TC Erciyes University

Summary

Peritonitis is currently one of the leading complications of continuous ambulatory peritoneal dialysis (CAPD). Aminoglycosides and vancomycin are used in the treatment of CAPD peritonitis despite their potential risk for ototoxicity. NAC is a molecule used in the treatment and prophylaxis of many diseases related to oxidative stress. The aim of this study was to examine whether ototoxicity due to antibiotics used in the treatment of CAPD peritonitis can be prevented by N-acetylcysteine

Detailed Description

NAC, a thiol-containing antioxidant because of this,we want to investigate antioxidant status.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•End-stage renal disease
•Undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy
•Developing the first continuous ambulatory peritoneal dialysis related peritonitis episode

Exclusion Criteria

•Being treated with aminoglycoside antibiotics and vancomycine within the previous 3 months
•Detection of mechanical occlusion of external ear
•Having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry
•History of a continuous ambulatory peritoneal dialysis related peritonitis

Locations (1)

Erciyes University

Kayseri, Turkey (Türkiye)

Key Dates

Start Date

June 1, 2010

Primary Completion Date

November 1, 2011

Completion Date

November 1, 2011

Last Updated

November 16, 2011

Enrollment

ACTUAL participants

Conditions

Hearing Loss, Extreme

Interventions

N-acetylcysteine

DRUG

Cochlear Implant Speech in Noise Processing

NCT06860152

Hearing Loss, Adult-OnsetSpeech Intelligibility+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 16, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions